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Abstract 
Anticoagulant and antiplatelet drugs are used and studied in numerous trials for primary and 
secondary prevention of atherothrombosis since decades. The annual rate for cardiovascular 
morbidity and mortality is high in patients following an acute coronary syndrome and in 
patients with peripheral arterial disease due to concomitant coronary and cerebrovascular 
diseases. Plaque rupture and subsequent thrombosis involves activation of both platelets and 
coagulation factors. Therefore the combination of aspirin and warfarin to improve prevention 
of atherothrombosis compared to antiplatelet therapy alone was studied but could not be 
established due to significantly increased risk of major bleeding compared to a non-significant 
reduction in ischemic events. During the past two decades, clinical trials focused on combined 
antiplatelet therapies in the prevention of secondary events following acute coronary 
syndromes and very recently on the new oral anticoagulants in combination with antiplatelet 
therapy. This review discusses the role the new oral anticoagulants such as Factor IIa 
(thrombin) and Factor Xa inhibitors in atherothrombosis, their pharmacological properties and 
recently published clinical data in secondary prevention of atherothrombotic events and 
potential implications for patients with peripheral arterial disease. 
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Highlights 
• Peripheral and coronary artery disease has a high ischemic event rate despite antiplatelet 
therapy.   
• Antiplatelet and anticoagulant agents inhibit different pathways of the coagulation 
pathway. 
• Combination of antiplatelet agents with novel oral Factor II or Factor X inhibitors may 
reduce ischemic events. 
• Combined antithrombotic therapy must carefully be tested for antithrombotic benefits and 
bleeding risk.  
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Introduction 
Atherothrombosis is defined by the occurrence of both atherosclerosis and thrombosis in an 
artery and results in myocardial, cerebral, limb and reno-mesenteric ischemia (1-4). Amongst 
the atherosclerotic diseases, patients with peripheral arterial disease (PAD) have an 
extensively large atherosclerotic burden, often coexisting coronary (CAD) and 
cerebrovascular disease, and have three times as high as the risk of myocardial infarction or 
stroke as patients without PAD (3, 5). Likewise, recurrent ischemic events are as high as 10% 
per annum following in acute coronary syndrome (6, 7) .  Despite antiplatelet therapy, up to 
10-20% of these patients still have cardiovascular events, indicating that the underlying 
atherothrombotic activity is not optimally controlled by antiplatelet agents. Therefore, the 
combination of antiplatelet therapy with oral anticoagulants to reduce atherothromcotic events 
has been studied in the Warfarin Antiplatelet Vascular Evaluation trial (WAVE) for patients 
with PAD (8, 9). This trial showed a non-significant reduction in ischemic events but a 
significant increase in bleeding complications (RR 3.41; 95% CI, 1.84-6.35) during an 
observation period of 35 months. The bleeding risk under combined antiplatelet and 
anticoagulant therapy is higher in PAD than in CAD without PAD. This might be attributable 
to different factors such as older age, vascular fragility and higher morbidity (10, 11). 
However, the combined antithrombotic therapy is not recommended for atherothrombosis in 
general (12) . 
Currently in the dawn of a new anticoagulant era with numerous new anticoagulant drugs that 
have either specific anti-thrombin or anti-FXa activity- compared to Vitamine K antagonists, 
that interfere in multiple ways in the coagulation cascade- more numerous trial for prevention 
and therapy of venous thromboembolism, prevention of embolic complication due to atrial 
fibrillation and therapy of atherothrombosis are reported and upcoming (13).  
Besides the afore mentioned increased risk of bleeding when combining antiplatelet drugs 
with Vitamin K antagonists, their narrow therapeutic windows, need for frequent laboratory 
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monitoring, food and drug interactions poses several disadvantages.  The development of 
novel oral factor Xa inhibitors and oral direct thrombin inhibitors provide an alternative to 
vitamin K antagonists. In this paper, we discuss the new agents, rivaroxaban, apixaban, and 
dabigatran, for secondary prevention of acute atherothrombosis and their therapeutic potential 
for patients with PAD and CAD.  
 
Atherothrombosis and ischemia 
Thrombosis plays a critical role in the pathomechanism of ischemic syndromes, as disruption 
of an atherosclerotic plaque exposes blood to subendothelial collagen, tissue factor, and other 
procoagulant molecules such as thrombin that trigger activation of platelets and formation of 
fibrin within the vessel lumen (14-16). Endothelial damage and dysfunction as well as 
inflammation and coagulation are closely related to the pathophysiology of ischemic 
syndromes (17). Platelets play key roles in both the formation of the atheromatous plaque and 
clinical presentation of acute atherothrombotic events following plaque rupture. In the 
pathogenesis of atherothrombosis, clotting activation has a crucial role and thrombin 
generation is involved both platelet activation and fibrin (Figure 1.). 
In animal models, hypercoagulability tends to increase atherosclerosis, whereas 
hypocoagulability reduces the atherosclerotic burden (18). If this direct relationship between 
coagulation and atherosclerosis applies for humans is not clear. Almost all coagulation 
proteins, including tissue factor, are found in atherosclerotic lesions in humans. In addition to 
generating local fibrin, an environment for cell growth, serine proteases such as thrombin are 
thought to be involved in cell signaling processes, acting through the activation of protease-
activated receptors (17). Activation of such protease-activated receptors on vascular cells 
triggers other complex processes promoting atherosclerosis, including inflammation, 
angiogenesis, and cell proliferation. 
Director thrombin inhibitors and anti-FXa-inhbitors are targeting at this crucial phase of 
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thrombin generation with the potential to prevent thrombosis and progression of 
atherosclerosis alike. Therefore, the novel anticoagulants may have synergistic antithrombotic 
and bleeding balance due to their pharmacodynamic and pharmacokinetic properties which 
combined with antiplatelet agents may improve overall net effects. Futhermore, combined 
therapy may be of benefit in aspirin resistance, which is both a clinical and laboratory 
problem (s. Kasmeridis, Apostollakis, Lip: Aspirin and Aspirn Resistance in Coronary 
Syndrome, in this issue of Current Opinion in Pharmacology). 
 
Novel anticoagulants 
In comparison to oral Vitamine K antagonist, either direct inhibitors of thrombin or factors Xa 
have overall favorable pharmacological effects . Examples of direct factor Xa inhibitors 
include apixaban, rivaroxaban, otamixaban, betrixaban and edoxaban. Direct thrombin 
inhibitors (factor IIa inhibitors) were developed with the limitations of standard heparin and 
warfarin in mind. Examples include ximelagatran, argatroban, and dabigatran etexilate. In 
common for these novel anticoagulants is the convenience of use with no requirement for 
laboratory monitoring and limited drug interactions, which may provide multifaceted 
treatment options for atherosclerosis and anticoagulation in the future (13). Due to the data 
available, this review discusses the two anti- Factor X inhibitors, rivaroxaban and apixaban, 
and the oral thrombin inhibitor dabigatran etexilate (Table 1)(19-22). There are differences 
between Factor Xa and thrombin that may cause these clotting factors to be affected 
differently by drugs that inhibit them. Currently, the only known functions of Factor Xa are 
promotion of coagulation and inflammation (23). Thrombin has more diverse actions in the 
body; in addition to its known effects on coagulation and inflammation, thrombin also 
activates protein C (which has anticoagulant properties) and promotes cellular proliferation . 
 
Rivaroxaban 
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Rivaroxaban is a direct factor Xa inhibitor with high and high plasma protein binding (92–
95%). In a concentration-dependent manner, rivaroxaban inhibits free factor Xa and 
prothrombinase-bound and clot-associated factor Xa. As a consequence, rivaroxaban prevents 
thrombin generation by inhibiting factor Xa generated via both the intrinsic and extrinsic 
coagulation pathways [4] but does no exhibit direct effect on platelet aggregation induced by 
collagen, adenosine diphosphate or thrombin (24).   
The pharmacokinetic profile of rivaroxaban shows favorable safety and tolerability profile. 
The bioavailability of a 10 mg dose of rivaroxaban is high (80–100%), and rivaroxaban is 
rapidly absorbed, reaching a maximal plasma concentration (Cmax) within 2–4 h after oral 
administration (Table 1). Rivaroxaban displays near linear pharmacokinetics, with a half-life 
of 7–11/11-13 h (for young/elderly subjects) and no significant accumulation after repeat 
dosing (ceiling effect). The pharmacokinetic profile is unaffected by food or antacids. 
Furthermore, there is no inhibition or induction of cytochrome-P-450 (CYPP450) isoforms. 
Rivaroxaban is elimintated in two-thirds through metabolic degradation in the liver, half of 
which is excreted via the kidneys and half via the hepatobiliary route. One-third of the dose is 
eliminated as unchanged drug in the urine. There are no active circulating metabolites of 
rivaroxaban.   
 
Apixaban 
Apixaban, like rivaroxaban, interrupts the coagulation cascade by blocking the enzymatic 
activity of Factor Xa (25, 26). Apixaban is a direct inhibitor of factor Xa . Orally administred 
apixaban reaches a bioavailability of 50% and Cmax is 3- 4 hours (Table 1). The half-life is 
10 - 14 h after repeated doses. Apixaban is metabolized in part by CYP3A4; it is partly 
eliminated by the kidneys (25%) and, to some extent, also processed via CYP-independent 
mechanisms in the liver. Similarly to rivaroxaban, apixaban does not induce or inhibit CYP 
enzymes and has a low likelihood of drug-drug or food-drug interactions.  
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Dabigatran etexilate 
Dabigatran directly inhibits both free and clot-bound thrombin. Dabigatran etexilate (a pro-
drug) is rapidly converted (after oral administration and hepatic processing) to dabigatran, 
with Cmax after 1.5 h after oral ingestion (Table 1). Dabigatran has a half-life of 14 -17 hours 
at steady state. In contrast to rivaroxaban, bioavailability is low with only 7.2%, and therefore 
it is predominantly excreted in the feces. Although part of the bioconversion from pro-drug to 
active metabolite occurs in the liver, the CYPP450 system is not involved. Potentially 
important drug interactions with quinine/quinidine and verapamil have been described. After 
hepatic activation, 80% of dabigatran is eliminated in the kidneys; thus, as for rivaroxaban 
and apixaban, patients with severe renal impairment have been excluded from most clinical 
trials.  
 
 
Clinical data for the novel oral anticoagulants in acute atherothrombosis 
All three novel oral anticoagulants have been evaluated in clinical trials for prevention of 
primary or secondary venous thromboembolism, and non-valvular atrial fibrillation and in 
addition for secondary prevention of atherothrombosis following acute coronary syndromes 
(phase III trials only for rivarocaban and apixaban). Table 2 compares antithrombotic effects 
and bleeding risk of different trials with new antiplatelet and anticoagulant agents. 
 
Rivaroxaban 
Rivaroxaban has been approved for the prevention primary or reccurent venous 
thromboembolism as well as for prevention of systemic embolization in non-valvular atrial 
fibrillation (27-29). However, the indication for prevention of recurrence of atherothrombosis 
was rejected July 2012 by the Food and Drug Administration due to increased bleeding risk in 
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patients with a recent acute coronary syndrome although rivaroxaban reduced the risk of the 
composite end point of death from cardiovascular causes, myocardial infarction, or stroke 
(19). Rivaroxaban increased the risk of major bleeding and intracranial hemorrhage but not 
the risk of fatal bleeding. In ATLAS ACS 2-TIMI 51, a double-blind, placebo-controlled trial 
published early in 2012, approximately 15’000 patients with a recent acute coronary 
syndrome received twice-daily doses of either 2.5 mg or 5 mg of rivaroxaban or placebo in 
addition to aspirin/clopidogrel (81% of patients with dual agents) for a mean of 13 months. 
The trials’ primary efficacy end point was a composite of death from cardiovascular causes, 
myocardial infarction, or stroke. Primary end point was 8.9% for rivaroxaban and 10.7% for 
placebo (hazard ratio 0.84; 95% confidence interval , 0.74 to 0.96; p=0.008), with significant 
improvement for both the twice-daily 2.5-mg dose (9.1% vs. 10.7%, p=0.02) and the twice-
daily 5-mg dose (8.8% vs. 10.7%, p=0.03). Remarkably, the twice-daily 2.5-mg dose of 
rivaroxaban reduced the rates of death from cardiovascular causes (2.7% vs. 4.1%, p=0.002) 
and from any cause (2.9% vs. 4.5%, p=0.002). In contrast, this survival benefit that was not 
achieved with the twice-daily 5-mg dose. As compared with placebo, rivaroxaban increased 
the rates of major bleeding (2.1% vs. 0.6%, p<0.001) and intracranial hemorrhage (0.6% vs. 
0.2%, p=0.009), without a significant increase in fatal bleeding (0.3% vs. 0.2%, p=0.66) or 
other adverse events. The twice-daily 2.5-mg dose resulted in fewer fatal bleeding events than 
the twice-daily 5-mg dose (0.1% vs. 0.4%, p=0.04). 
 The striking finding of ATLAS ACS 2-TIMI 51 is that the survival benefit for rivaroxaban 
was only observed with the 2.5-mg twice-daily dose, one quarter of the dose studied in atrial 
fibrillation or venous thromboembolism, but again suggesting that higher doses may offset the 
benefit with more bleeding events.  
 
Apixaban 
The APPRAISE-2 trial  (apixaban after acute coronary syndromes) contrasts the ATLAS ACS 
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2-TIMI 51 since it was stopped early due to a highly significant increase in major bleeding 
without any relevant reduction in ischemic events (30). Only after a median follow-up of 241 
days, the primary outcome of cardiovascular death, myocardial infarction, or ischemic stroke 
occurred 7.5% assigned to apixaban  and in 7.9% assigned to placebo (hazard ratio with 
apixaban, 0.95; 95% confidence interval, 0.80 to 1.11; p=0.51). The primary safety outcome 
of major bleeding occurred in 1.3% who received apixaban and in 0.5% with placebo (hazard 
ratio with apixaban, 2.59; 95% confidence interval, 1.50 to 4.46; p=0.001). A greater number 
of intracranial and fatal bleeding events occurred with apixaban than with placebo (0.3/0.1 % 
vs. 0.1/0 %).  
 
Dabigatran etexilate 
There is only dose findings study (phase II) for the oral direct thrombin inhibitor dabigatran 
etexilate (RE-DEEM) (31-33). In the RE-DEEM trial, with almost all patients receiving dual 
platelet inhibition, a dose-dependent increase in clinically relevant bleeding events was 
observed, with highest rates with the dabigatran etexilate 110 mg and 150 mg twice daily as 
currently used in atrial fibrillation. The most frequently reported bleeding events were 
gastrointestinal bleeding and epistaxis. The study was not powered to demonstrate an efficacy 
difference in cardiovascular death, nonfatal myocardial infarction or nonhemorrhagic stroke, 
but a numerically lower proportion was attained in the 2 higher dabigatran doses (110 mg 
twice daily., 3.0%; 150 mg twice daily., 3.5%) compared with the lower doses (50 mg twice 
daily., 4.6%; 75 mg twice daily., 4.9%) and the placebo group (3.8%). 
 
Other emerging anticoagulants 
Darexaban, another Factor IIa Inhibitor, was evaluated for safety and tolerability for the 
prevention of ischemic events in acute coronary syndromes (34). Darexaban, when added to 
dual antiplatelet therapy, produced a dose-related 2- to 4-fold increase in bleeding versus 
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placebo, with no other safety concerns, but also with no efficacy. 
 
Discussion: 
The are two new oral anticoagulant drugs with phase III studies that were conducted for 
secondary prevention of atherothrombotic events (The APPRAISE-2 trial and ATLAS  ACS 
2–TIMI 51) - of which the APPRAISE was prematurely terminated because of an excess of 
bleeding with apixaban and no evidence of benefit (19, 30). There was no phase III trial for 
dabigatran based on similar issues following the phase II study and on findings suggesting an 
increased risk of myocardial ischemia (33). Only the ATLAS ACS 2–TIMI 51 met its primary 
objective but also with a three to four fold increase in intracranial bleedings (31).  
This differences between APPRAISE-2 and ATLAS ACS 2 TIMI 51 is not well explained 
bydifferent bleeding rates, which was increased to a similar extent in both trials. The 
APPRAISE-2 population was older and more commonly, had diabetes, renal insufficiency, 
and history of stroke, and more severe myocardial ischemia (32). The higher risk population 
included in the APPRAISE-2 study was reflected by a higher rate of the primary efficacy 
outcome. This may be attributable to a different pathophysiology—and eventually be less 
related to thrombotic events and thereby less responsive to anticoagulant treatment—than in 
the ATLAS-2 trial. In addition, FXa inhibition potency of the studied doses was different: 
APPRAISE-2 used the same 5 mg twice daily apixaban dose tested in atrial fibrillation, 
whereas ATLAS-2 used 2  doses ( 2.5 mg/ 5 mg twice daily), that were one fourth to one half 
of the total daily dose of rivaroxaban (20 mg once daily) tested in atrial fibrillation. This 
might hypothetically suggest that a lower, rather than a higher, level of FXa inhibition per se 
may have a better antithrombotic effect. 
Taken together, the combination of a dual antiplatelets therapy with a novel oral anticoagulant 
is associated with dose-dependent increased risk for major and intracranial bleeding risk and 
only with rivaraoxaban with a significantly lower rate of ischemic related deaths. Although 
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the American Food and Drug administration did not approve rivaraoxban for secondary 
prevention of acute coronary syndrome, ATLAS ACS 2-TIMI 51 provides evidence that 
reduction of the persistently high morbidity and mortality after myocardial ischemia is 
possible (Figure 2).  So far, combination of antithrombotic therapy has shifted the ischemic-
bleeding balance in a parabolic function with slightly lower recurrent atherothrombosis but 
higher risk for major bleeding, or vice versa. Nevertheless, the combination of only one 
antiplatelet agent (aspirin) with one new oral anticoagulant - of which rivaroxaban at a dosage 
of 2.5 mg twice daily seems to be the candidate- might be tempting for patient with PAD. In 
contrast to patients with a recent acute coronary syndrome, patients with PAD at a chronic 
stage are not treated by dual antiplatelets drugs irrespective of their risk for atherothrombotic 
events. Therefore, a logic consequence would be a trial -similar to the WAVE study (warfarin 
and aspirin) - with aspirin and low dose rivaroxaban (8). With regard to the high incidence of 
atherothrombotic events in this atherosclerotic subgroup, an improved therapy for secondary 
prevention is still needed for PAD.  The main safety issue with bleeding risk will jeopardize 
the potential antithrombotic benefit, and patients with PAD are usually older and more fragile. 
Hence, PAD patients with previous cerebral ischemia or major bleedings should be evaluated 
with great caution. In contrast to WAVE trial with warfarin and a target international 
normalized ratio of 2.0 to 3.0, a trial with rivaroxaban 2.5mg combined with aspirin 
represents a lower bleeding risk, since 2.5mg of rivaroxaban is a quarter of the dosage that is 
used for atrial fibrillation. 
In conclusion, atherothrombosis is often insufficiently controlled by antiplatelet therapy alone. 
Combination of antiplatelet agents with novel anticoagulants may reduce ischemic events but 
is associated with an increased risk for major bleedings. So far, no novel anticoagulant drug is 
approved for secondary prevention following acute coronary syndrome. PAD patients are a 
fragile subgroup of atherosclerotic patients with substantial risk for atherothrombotic events 
and need to be carefully evaluated for combined antithrombotic therapy with the novel 
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anticoagulants.   
 
Legends 
 
Figure 1. Simplified coagulation and clotting cascade in atherothrombosis and antithrombotic  
drug actions. 
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Figure 2. Rates of recurrent atherothrombotic and bleeding events in patients with 
symptomatic atherosclerosis. The parabolic function indicates that in dependence of 
antithrombotic agents the risk shifts towards either higher bleeding or higher ischemic risk. 
Ideally the shift should tend towards both lower ischemic and bleeding events (dotted line). 
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